Data Driven Paths to Advancing Precision Medicine Strategies for Parkinson’s Disease: Critical Path for Parkinson’s Consortium
Objective: An update on the accomplishments of the Critical Path for Parkinson’s (CPP) Consortium. Background: The pharmaceutical pipeline for Parkinson’s disease (PD) is rapidly expanding. Data sharing will facilitate decision making during the development…A Milestone-based approach to monitoring disease progression in Parkinson’s disease
Objective: We used Parkinson Progression Marker Initiative (PPMI) data to assess the frequency of clinically meaningful disease milestones and examine baseline predictors of reaching these…Azathioprine immunosuppression and disease modification in Parkinson’s disease (AZA-PD): a randomised double-blind placebo-controlled phase II clinical trial
Objective: To design a clinical trial to test the concept that the immune system is integral in the progression of Parkinson’s disease (PD) and establish…Efficacy of a 6-week brisk walking program in improving non-motor symptoms in people with Parkinson disease – a randomized controlled trial
Objective: To examine whether the brisk walking program would be effective in alleviating non-motor symptoms, and improving sleep quality and health-related quality-of-life (HRQoL) in people…RESPONDING TO COVID-19: THE “ALMEIDA-SANG EQUATION” TO PREDICT TOTAL DISEASE SEVERITY IN PARKINSON’S
Objective: To predict total disease severity in Parkinson’s disease (PD) for online assessments. Background: Assessment (and hence management) of PD has largely been affected by…Comparison of Antiparkinsonian Medication Initiation and Levodopa-Equivalent Daily Dose Across PPMI, STEADY-PD III, and SURE-PD3
Objective: To compare use of antiparkinsonian medications (APM) among early Parkinson disease (PD) patients across clinical study cohorts. Background: Initiation of APM is a key…Influence of onset of motor fluctuations on the effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations: findings from the real-world OPTIPARK study
Objective: This post-hoc analysis evaluated the influence of onset of motor fluctuation (OMF) on the response to opicapone (OPC) treatment in patients with Parkinson’s disease…Effect of H. pylori Infection on L-DOPA Pharmacokinetics in Patients with Parkinson’s disease.
Objective: To evaluate whether Helicobactor pylori (H.pylori) infection affects the pharmacokinetics of L-DOPA in patients with Parkinson’s disease (PD). Background: H. pylori infects gastric mucosa…Pilot study of Phenotype of Antisense-Oligonucleotide-(ASO)-knockdown of Cerebral-Dopamine-Neurotrophic-Factor (CDNF) as Parkinson Disease model : implications for PD and related Dementia Therapeutics
Objective: Our objective is twofold: 1)to examine whether CDNF-ASO paradigm can induce a unique phenotype mimicking PD/PDD/LBW in the rodent species; 2) to evaluate whether…Coffee, smoking and aspirin are associated with age at onset and clinical severity in idiopathic Parkinson’s disease
Objective: To investigate a possible association between smoking, the consumption of caffeine and the use of aspirin on age at onset (AAO), motor and non-motor…
- « Previous Page
- 1
- …
- 270
- 271
- 272
- 273
- 274
- …
- 338
- Next Page »